| Revenue growth | 23.1% YoY for FY26. |
|---|---|
| Margins | Near-term dilution due to expansion; mature centers at 36-37%. |
| Demand visibility | Strong traction in genomics and advanced radiology segments. |
| Management confidence | High, focus on replicating high-margin model in new territories. |
Growth
FY26 Revenue grew 22.5% to INR 3136M; PAT at INR 314M. EBITDA margins at 31.8%.
Outlook
FY27 Revenue guidance ~15%; EBITDA guidance 33%. Capex planned at INR 70cr for 5 hubs and 8 spokes.
Risks
EBITDA margin compression from 33.8% to 31.8% due to high fixed costs of rapid new center expansion.
Earnings Call filed with NSE, NSE: SURAKSHA. Summary written with AI assistance from the document.
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹324.10
- Market cap
- ₹1,688 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 47.1×Sector 53.1×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suraksha Diagnostic Ltd
All →Suraksha Diagnostic Annual General Meeting
Suraksha Diagnostic Ltd held its 21st AGM on September 22, 2026. Members adopted financial statements, approved a final dividend, and ratified cost auditor remuneration.
Suraksha Diagnostic Annual General Meeting
Suraksha Diagnostic Limited has issued a notice for its 21st Annual General Meeting scheduled for September 22, 2026, to conduct routine business and dividend declaration.
- Value
- ₹0.01 Cr
Suraksha Diagnostic Annual General Meeting
Suraksha Diagnostic Limited has issued a notice for its 21st Annual General Meeting to be held on September 22, 2026, to transact key corporate business.
Suraksha Diagnostic Other Announcement
Suraksha Diagnostic informed exchanges about dispatching letters to shareholders with unregistered emails, providing web links to access the 21st AGM notice and Annual Report.
Suraksha Diagnostic Annual Report
Suraksha Diagnostic Limited has filed its Annual Report for FY 2025-26, including the notice for the 21st Annual General Meeting scheduled for September 22, 2026.
Suraksha Diagnostic Earnings Call Transcript: Key Takeaways
Suraksha Diagnostic reported a robust Q1 FY27 with 21% revenue growth and 40% PAT growth, driven by expansion in West Bengal and Jharkhand and a high-growth genomics segment.
- Call
- Guides 15% growth